Vanguard Group Inc Athira Pharma, Inc. Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATHA
# of Institutions
83Shares Held
22.3MCall Options Held
77.1KPut Options Held
42.4K-
Perceptive Advisors LLC New York, NY5.4MShares$13.9 Million0.31% of portfolio
-
Baker Bros. Advisors LP New York, NY3.15MShares$8.11 Million0.11% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$3.84 Million2.38% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$3.84 Million0.26% of portfolio
-
Bml Capital Management, LLC Zionsville, IN900KShares$2.31 Million1.65% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $97.2M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...